Management of Malignant Pleural Effusions

Management of Malignant Pleural Effusion

“…Selection of optimal treatment for each individual patient requires a careful assessment of the benefits and the risks of the treatment. Primary treatment targets should involve palliation or elimination of dyspnea, improvement of a patient's overall quality of life in order to restore daily activities, and implementation of oncological therapies [102]. Treatment options include repeat thoracentesis, tube thoracostomy with drainage and sclerosis with chemical sclerosant agents, chronic indwelling pleural catheter, pleuroperitoneal shunt, intrapleural or systemic chemotherapy, thoracoscopy with drainage and talc insufflation, and pleurectomy [78].…”

Quinazoline and tetrahydropyridothieno[2,3-d]pyrimidine derivatives as irreversible EGFR tyrosine kinase inhibitors: influence of the position 4 substituent

“…Members of the epidermal growth factor receptor (EGFR) family were found to play a vital role in lung tumorigenesis being overexpressed in 40-80% of non-small cell lung carcinoma (NSCLC) tumors. [1][2][3][4] A series of downstream signaling events results from EGFR activation and can mediate cancer cell growth, proliferation, motility, adhesion, invasion, apoptosis inhibition and metastasis as well as resistance to chemotherapy. Accordingly, EGFR inhibitors would be valuable in cancer treatment.…”

“…Accordingly, EGFR inhibitors would be valuable in cancer treatment. 1,2 Getinib, erlotinib, and lapatinib (Fig. 1) are examples of small molecules, acting as kinase inhibitors, that have been approved in cancer treatment.…”